Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Results for uni: and multivariate logistic regression analysis of risk factors for eligibility to anti-osteoporosis medications. | Not eligible for AOM (N = 237) | Eligible for AOM (N = 69) | Univariate analysis OR [95%CI] | P-value | Multivariate analysis OR [95%CI] | P-value: 25 (OH) vitamin D level (ng/ml) | 26.3 ± 9.6 | 24.2 ± 10.2 | 0.98 [0.95 to 1.01] | 0.12 | |

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A Single-center, descriptive, cross-sectional study was conducted at Lille University Hospital.

Source: Methods.

The patients were prospectively referred between June 2019 and January 2025.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Bone Health and Anti-Osteoporotic Medication Eligibility in Postmenopausal Women Undergoing Bariatric Surgery: The Impact of Age and Modifiable Risk Factors

Cross-sectional study · Calcified Tissue International · 2026

Original publication title

Bone Health and Anti-Osteoporotic Medication Eligibility in Postmenopausal Women Undergoing Bariatric Surgery: The Impact of Age and Modifiable Risk Factors

Line Abdulghani; Hélène Verkindt; Laurine Cadart; Cécile Philippoteaux; Robert Caiazzo; Julien Paccou

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Nearly one in five postmenopausal women undergoing MBS were eligible for AOM based on the ECTS position statement, with prevalence doubling after 60 years (OR = 2.34). Active smoking, secondary hyperparathyroidism, and low ALMI were key independent risk factors. These findings underscore the importance of systematic bone health assessment and early implementation of lifestyle interventions, alongside AOM, to reduce fracture risk in this vulnerable population.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Postoperative complications after metabolic and bariatric surgery (MBS) increase with age, yet data on bone health in older postmenopausal women remain limited. The 2022 European Calcified Tissue Society (ECTS) position statement recommend anti-osteoporotic medication (AOM) for patients with a T-score ≤ −2 and/or a fragility fracture within the past two years. This study evaluated the prevalence of AOM eligibility according to age (< 60 vs. ≥ 60 years) in postmenopausal women and identified associated risk factors.

Source: Introduction

Abstract: What methods does the paper describe?

We conducted a cross-sectional, observational, single-center study at Lille University Hospital including postmenopausal women referred for bone health evaluation before or after MBS. AOM eligibility was defined according to the 2022 ECTS criteria.

Source: Materials and Methods

Abstract: Results

Among 306 postmenopausal women, 173 were < 60 years (group 1) and 133 were ≥ 60 years (group 2). Overall, 69 patients (22.5%) were eligible for AOM, with a significantly higher prevalence in women ≥ 60 years (30.1% vs. 16.8%, p = 0.006). In multivariate analysis, independent predictors of AOM eligibility were age ≥ 60 years (OR = 2.34, 95% CI: 1.19 to 4.61), active smoking (OR = 2.98, 95% CI: 1.27 to 7.02), reduced appendicular lean mass index (ALMI < 5.5 kg/m2; OR = 3.72, 95% CI: 1.78 to 7.78), and elevated iPTH (OR = 1.15, 95% CI: 1.05 to 1.25 per 10 ng/mL increase).

Source: Results

Abstract: Conclusion

Nearly one in five postmenopausal women undergoing MBS were eligible for AOM based on the ECTS position statement, with prevalence doubling after 60 years (OR = 2.34). Active smoking, secondary hyperparathyroidism, and low ALMI were key independent risk factors. These findings underscore the importance of systematic bone health assessment and early implementation of lifestyle interventions, alongside AOM, to reduce fracture risk in this vulnerable population.

Source: Conclusion
Authors’ abstract

Introduction

Postoperative complications after metabolic and bariatric surgery (MBS) increase with age, yet data on bone health in older postmenopausal women remain limited. The 2022 European Calcified Tissue Society (ECTS) position statement recommend anti-osteoporotic medication (AOM) for patients with a T-score ≤ −2 and/or a fragility fracture within the past two years. This study evaluated the prevalence of AOM eligibility according to age (< 60 vs. ≥ 60 years) in postmenopausal women and identified associated risk factors.

Materials and Methods

We conducted a cross-sectional, observational, single-center study at Lille University Hospital including postmenopausal women referred for bone health evaluation before or after MBS. AOM eligibility was defined according to the 2022 ECTS criteria.

Results

Among 306 postmenopausal women, 173 were < 60 years (group 1) and 133 were ≥ 60 years (group 2). Overall, 69 patients (22.5%) were eligible for AOM, with a significantly higher prevalence in women ≥ 60 years (30.1% vs. 16.8%, p = 0.006). In multivariate analysis, independent predictors of AOM eligibility were age ≥ 60 years (OR = 2.34, 95% CI: 1.19 to 4.61), active smoking (OR = 2.98, 95% CI: 1.27 to 7.02), reduced appendicular lean mass index (ALMI < 5.5 kg/m2; OR = 3.72, 95% CI: 1.78 to 7.78), and elevated iPTH (OR = 1.15, 95% CI: 1.05 to 1.25 per 10 ng/mL increase).

Conclusion

Nearly one in five postmenopausal women undergoing MBS were eligible for AOM based on the ECTS position statement, with prevalence doubling after 60 years (OR = 2.34). Active smoking, secondary hyperparathyroidism, and low ALMI were key independent risk factors. These findings underscore the importance of systematic bone health assessment and early implementation of lifestyle interventions, alongside AOM, to reduce fracture risk in this vulnerable population.

Publication and source details

Original title: Bone Health and Anti-Osteoporotic Medication Eligibility in Postmenopausal Women Undergoing Bariatric Surgery: The Impact of Age and Modifiable Risk Factors

Line Abdulghani; Hélène Verkindt; Laurine Cadart; Cécile Philippoteaux; Robert Caiazzo; Julien Paccou

Calcified Tissue International · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Centre Hospitalier Universitaire de Lille

Open access funding provided by Centre Hospitalier Universitaire de Lille.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:15:31.722708+00:00

DOI: 10.1007/s00223-026-01484-z · PMC12858525